BioLargo (BLGO): Nov 2 Form 8-K, AEC PFAS Water Treatment Commercialization & CleanTech Valuation vs. ERII, XYL, PWTN
BLGO
BioLargo, Inc. (OTCQX: BLGO) operates a commercial clean-technology and life-sciences portfolio anchored by its patented Aqueous Electrostatic Concentrator (AEC) for per- and polyfluoroalkyl substances (PFAS) water remediation, alongside its Clyra Medical Technologies antimicrobial wound-care subsidiary and Odor-No-More industrial division. On November 2, 2026, BioLargo filed a Current Report on Form 8-K updating shareholders on corporate and operational developments across its commercial divisions.
With the U.S. EPA enforcing strict 4 parts-per-trillion (ppt) drinking-water limits on PFOA and PFOS, municipal utilities face spent-carbon disposal bottlenecks where BioLargo's AEC system reduces PFAS-laden solid waste volume by more than 99% compared to granular activated carbon (GAC). Trading near $24.1 million on OTCQX, BLGO offers multi-shot commercial optionality across water, medical, and battery storage.
Sector Peer Valuation & Catalyst Comparison
| Ticker | Company | Exchange | Market Cap | Primary Catalyst / Focus |
|---|---|---|---|---|
| BLGO (Subject) | BioLargo, Inc. | OTCQX | $24.1M | PFAS Water Remediation, CleanTech & Medical Wound Care (2026-11-02 8-K) |
| ERII | Energy Recovery, Inc. | Nasdaq | $890M | Pressure-exchanger desalination & industrial wastewater treatment |
| Montrose | Montrose Environmental (MEG) | NYSE | $720M | PFAS water remediation & environmental engineering services |
| TTEK | Tetra Tech, Inc. | Nasdaq | $11.8B | Municipal water infrastructure & PFAS compliance engineering |
Verified SEC EDGAR Filing Metrics (BLGO · CIK 0000880242)
| Form | Filing Date | Disclosure Scope | EDGAR Source |
|---|---|---|---|
| 8-K | 2026-11-02 | SEC Form 8-K (Items: 7.01,9.01) | View EDGAR Filing → |
| DEF 14A | 2026-10-19 | SEC Form DEF 14A | View EDGAR Filing → |
| 8-K/A | 2026-09-14 | SEC Form 8-K/A (Items: 7.01,9.01) | View EDGAR Filing → |
| 8-K | 2026-09-11 | SEC Form 8-K (Items: 7.01,9.01) | View EDGAR Filing → |
| 10-Q | 2026-08-14 | SEC Form 10-Q | View EDGAR Filing → |
| 10-Q | 2026-05-15 | SEC Form 10-Q | View EDGAR Filing → |
| 8-K | 2026-05-06 | SEC Form 8-K (Items: 7.01,9.01) | View EDGAR Filing → |
| 8-K | 2026-05-04 | SEC Form 8-K (Items: 7.01,9.01) | View EDGAR Filing → |
What Active Traders & Microcap Desks Are Watching Next
Active clean-tech traders and family offices are tracking additional municipal water utility contracts for the AEC PFAS platform, commercial revenue recognition from Clyra Medical's national surgical distribution partners, and Cellinity liquid-sodium battery validation.
Primary sources (SEC EDGAR)
BLGO Form 8-K (2026-11-02): https://www.sec.gov/Archives/edgar/data/880242/000143774926034271/blgo20261101_8k.htmBLGO Form DEF 14A (2026-10-19): https://www.sec.gov/Archives/edgar/data/880242/000143774926032868/blgo20261014_def14a.htmBLGO Form 8-K/A (2026-09-14): https://www.sec.gov/Archives/edgar/data/880242/000143774926030198/blgo20260911_8ka.htmBLGO Form 8-K (2026-09-11): https://www.sec.gov/Archives/edgar/data/880242/000143774926030124/blgo20260910_8k.htmSee the dilution and promotion flags before you see the pitch.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.